Atenolol-Induced Hyperglycemia: Clinical Implications and Recommendations

Mechanism and Evidence

Beta-blockers, including atenolol, increase the risk of new-onset diabetes by approximately 22% compared to non-diuretic antihypertensive agents, according to the American Heart Association 1, 2
Atenolol specifically has a higher risk for causing new-onset type 2 diabetes, particularly in elderly patients and with longer duration of treatment, as reported by the American College of Cardiology 1, 2

First and second-generation beta-blockers like atenolol are associated with unfavorable changes in blood lipid profiles, including increased very low-density lipoprotein (VLDL) and triglyceride concentrations and decreased high-density lipoprotein (HDL) cholesterol levels, as noted by the American Society of Hypertension 3, 4

The European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines acknowledge the diabetogenic effect of beta-blockers like atenolol and recommend caution, with a strength of evidence classified as high 5, 6
In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), atenolol-based therapy was inferior to amlodipine-based therapy in patients with diabetes, with higher rates of cardiovascular events and stroke, as reported by the European Society of Cardiology 1, 2

For hypertensive patients with or at risk for diabetes, consider alternative antihypertensive agents such as ACE inhibitors, angiotensin receptor blockers, or calcium channel blockers, which have more favorable metabolic profiles, as recommended by the European Society of Hypertension and the American College of Cardiology 1, 2, 5
Monitor blood glucose levels regularly in patients taking atenolol, particularly during the initial months of therapy, as advised by the American Society of Hypertension 3, 4
Be aware that atenolol may mask hypoglycemic symptoms in diabetic patients, requiring additional vigilance and patient education, as noted by the American Diabetes Association 3, 4